Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific (BSX) stock fell 6% after the medical device maker cut its Q4 sales and full-year EPS guidance due to ongoing disruptions from an August cyberattack. The company estimated the eight-day cyberattack cost it 300 basis points in sales growth and $0.07 in adjusted EPS. Management expects a slow recovery with 2027 projected as the trough year, though the stock now trades at a relatively low 13x forward earnings multiple.

10/28/2026, 4:50 PM • The Motley Fool

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale

The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.

10/21/2026, 5:00 AM • GlobeNewswire

How Many Shares Would It Take to Earn $1,000 a Year From This Future Dividend King?

Medtronic is one year away from achieving Dividend King status with 49 consecutive years of dividend increases. An investor would need approximately 348 shares (costing ~$32,792) to generate $1,000 in annual dividend income at the current 3% yield. The recent MiniMed spinoff positions Medtronic to focus on higher-margin businesses, potentially enabling larger dividend increases and earnings growth of 7-8% in coming years.

10/17/2026, 8:06 AM • The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

10/12/2026, 2:40 PM • The Motley Fool

4 Healthcare Stocks Worth Owning for the Next Decade

The article recommends four healthcare stocks across two key niches: GLP-1 weight-loss drugs (Eli Lilly and Novo Nordisk) and surgical robotics (Intuitive Surgical and Medtronic). Eli Lilly leads in GLP-1 but faces patent expiration risks, while Novo Nordisk is a turnaround story with attractive valuation. Intuitive Surgical dominates surgical robotics with strong recurring revenue, while Medtronic offers a diversified play with dividend appeal as it launches its Hugo surgical robot.

10/12/2026, 11:15 AM • The Motley Fool

China Airway Management Market Forecast to 2033 - Airway Management Tubes and Intubation Accessories | Revenue, Volume, Pricing, Company Share, and Growth Opportunities

ResearchAndMarkets.com released a comprehensive market report on China's airway management sector, covering historical data from 2018 and forecasts through 2033. The report segments the market into Airway Management Tubes and Intubation Accessories, providing revenue, volume, and pricing analysis. It includes 2025 company share data and profiles of key competitors to support strategic planning and investment decisions in this growing medical device market.

10/09/2026, 4:58 AM • GlobeNewswire

The "Trumpflation" Trade Could Get Worse Before It Gets Better. History Says These 2 Stocks Are the Place to Hide.

As inflation concerns persist amid Middle East geopolitical tensions and rising energy prices, healthcare stocks are positioned as defensive investments. Medtronic, a turnaround story with strong dividend history and accelerating growth, appeals to value investors. Eli Lilly, a GLP-1 drug leader expanding its pipeline, offers growth potential. Both companies benefit from healthcare's historical resilience to inflation.

10/06/2026, 10:15 PM • The Motley Fool

Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight

The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.

10/06/2026, 1:00 PM • GlobeNewswire

Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October

Despite recent Fed rate hikes and rising Treasury yields, the article recommends two blue chip dividend stocks: AbbVie, a Dividend King with 53 consecutive years of dividend increases and strong growth prospects from new drugs, and Medtronic, which is on track to become a Dividend King with 49 consecutive years of dividend hikes and improving operational performance after recent restructuring.

10/05/2026, 3:15 PM • The Motley Fool

2 High-Yield Stocks to Buy in October Without Any Hesitation

The author recommends two high-yield dividend stocks for October: Medtronic (MDT), which has completed a business overhaul and is approaching Dividend King status with a 3.3% yield, and McCormick (MKC), a consumer staples company with 39 years of dividend increases and a 4.2% yield that is acquiring Unilever's food business to roughly double its sales.

10/04/2026, 11:15 AM • The Motley Fool

Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way.

As Wall Street anticipates potential Fed rate hikes, healthcare stocks are positioned to weather economic uncertainty better than other sectors. Three healthcare companies—Eli Lilly, Medtronic, and Johnson & Johnson—are highlighted as resilient investments due to their strong fundamentals, diversified portfolios, and proven ability to generate growth regardless of interest rate environment.

10/03/2026, 7:15 PM • The Motley Fool

Cardiorespiratory Assessment Units Market Poised for Growth Through 2035 as Advanced Technologies and Expanding Clinical Applications Create New Opportunities

The global Cardiorespiratory Assessment Units Market is projected to grow from USD 1.48 billion in 2025 to USD 2.98 billion by 2035, expanding at a CAGR of 7.23%. Growth is driven by rising prevalence of COPD and heart failure, innovation in portable AI-enabled systems, and expanding remote care applications. However, high equipment costs and staffing requirements remain challenges. North America leads with 35.12% market share.

09/25/2026, 4:58 AM • GlobeNewswire

Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig

ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic decision-making for manufacturers, investors, and healthcare stakeholders.

09/24/2026, 5:54 AM • GlobeNewswire

2 Beaten-Down Stocks to Buy Before They Bounce Back

Shopify and Intuitive Surgical, despite significant year-to-date declines of 19% and 29% respectively, present attractive buying opportunities. Shopify's strong Q2 results and AI-powered initiatives position it well in e-commerce, while Intuitive Surgical's market leadership in robotic-assisted surgery and high switching costs provide competitive advantages despite increased competition from Medtronic.

09/22/2026, 6:33 PM • The Motley Fool

R3 Vascular Appoints Lisa Wipperman Heine to its Board of Directors

R3 Vascular Inc., a medical device company developing bioresorbable scaffolds for peripheral arterial disease treatment, announced the appointment of Lisa Wipperman Heine to its Board of Directors. Heine brings over 30 years of medical technology industry experience, including previous CEO roles and board positions at multiple medical device companies. The appointment comes as R3 Vascular accelerates clinical trials and prepares for commercialization of its MAGNITUDE® technology platform.

09/21/2026, 10:00 AM • GlobeNewswire